The findings went beyond anyones cautious hopes
The PI3K/Akt/FOXO1 pathway might be involved in the regulation of Th17/Treg balance by exenatide, while FOXO1 inhibitors could block the regulatory effect of exenatide on Th17/Treg balance
Stemming from these insights, researchers initiated the creation and enhancement of dual-receptor stimulants targeting both GLP-1/glucagon, aiming to counteract DM2 and obesity
Phase 2 Metabolic Benefits Beyond weight loss, retatrutide improved cardiometabolic markers: Blood pressure: Systolic BP decreased 7.4 mmHg (12mg dose) Triglycerides: Reduced 27% from baseline Fasting glucose: Decreased 13.8 mg/dL HbA1c: Reduced 0.4% (in participants without diabetes) TRIUMPH-4: First Phase 3 Results (December 2025) TRIUMPH-4 was the first Phase 3 trial to report
Hypothalamic ER-associated degradation regulates POMC maturation, feeding, and age-associated obesity
Description Retatrutide 40mg A Retatrutide 40mg is the next-generation triple-agonist peptide developed for advanced scientific and metabolic research applications
